64 results about "Immunodeficiency disease" patented technology

Methods of treating, preventing and / or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed.

The invention discloses a health food for improving immunity and a preparation method thereof. The health food is prepared from the following raw materials in part by weight: 1 to 3 parts of dendrobium officinale, 2 to 6 parts of American ginseng and 6 to 18 parts of Chinese wolfberry. Pharmacological experiments prove that: the health food has an obvious effect of promoting an immune system, canobviously improve a phagocytic index of macrophage of immunosuppressed mice and increase coefficients of immune organs in nonspecifc immune experiments, can improve the conversion rate of lymphocytes, improve the level of immunoglobulin IgG, IgA and IgM in serum of the immunosuppressed mice and assist in conditioning immunodeficiency disease, and diseases such as weakened immune system, low resistance and the like.

A novel HIV type O immunodeficiency virus is disclosed which has the designation MVP-2901 / 94 and which has been deposited with the European collection of animal Cell Cultures (ECACC) under No. V 950121601. The characteristic antigens which can be obtained from the virus and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the partial DNA and amino acid sequences of the virus.

The invention discloses a spleen extract prepared from mammalsí» spleens through fat-removing, homogenating, comminuting, settling and hyperfiltrating, and comprises the following constituents: polypeptides, free amino acid, nucleic acid and total sugar. The spleen extract can be used for preparing medicament for the treatment of cell immunodeficiency diseases, respiratory tract and lung infection, chronic hepatitis B, mumps, aphtae, leucopenia, leukemia, regenerative anemia, and malignant tumour.

An agaricus bisporus polysaccharide with immunocompetence is a heteropolysaccharide consists of ribose, rhamnose, arabinose, xylose, mannose, glucose, and galactose at a molar ratio of 2.08:4.61:2.45:22.25:36.45:89.22:1.55. The agaricus bisporus polysaccharide is prepared by extracting agaricus bisporus in a water bath; precipitating the extract with ethanol; deproteinizing the precipitate to obtain coarse polysaccharide; processing the coarse polysaccharide by ion exchange column chromatography with an anion exchange packing; eluting with distilled water; carrying out freeze drying; carrying out gel chromatography; eluting with distilled water; carrying out freeze drying to obtain the final product. The agaricus bisporus polysaccharide has immunological enhancement effect, and can serve as adjuvant drug for treating immunodeficiency diseases, such as cancer, or serve as functional health products and foods for enhancing immunity.

This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.

A process for expressing thymopeptide alpha 1 by colibacillus includes PCR amplification to obtain the full-length gene of thymopeptide alpha 1, endonuclease severing at both ends, and cloning to colibacillus for stable expression. After purified, it can be used as injection to treat immunodeficiency diseases.

The invention discloses a method for constructing a CHO cell strain for stably and efficiently expressing a human serum albumin and an interleukin II fusion protein. The CHO monoclonal cell strain for stably and efficiently expressing the human-derived recombinant protein can be obtained by electrically transferring a plasmid with the human serum albumin and the interleukin II fusion gene into the CHO cell. The monoclonal cell strain obtained by the invention is capable of secretory expression of the human serum albumin and the interleukin II fusion protein, the protein expression quantity is high, and the fusion protein can be obtained through the separation and purification; the in vitro biological activities of two fusion proteins are higher than the mol monomer 1L-2 activity. The CHO cell strain can be widely applied to the medicines for treating various diseases such as tumor, hepatitis, pneumonia and immunodeficiency disease.

The invention discloses application of ginsenoside Rh2 and particularly verifies that ginsenoside can be applied to preparation of inhibitors for inhibiting Treg cells or preparation of compositions for preventing and / or treating tumors with Treg cells increased. The ginsenoside Rh2 is capable of improving balance of T cells in human bodies by inhibition of the Treg cells, autoimmunity can be further enhanced, and accordingly an anti-tumor effect or an immunodeficiency disease improvement effect can be achieved.

The invention relates to the field of a preparation method and application of a traditional Chinese medicine effective component and in particular relates to a preparation method of rhizoma polygonatipolysaccharide and application of the rhizoma polygonati polysaccharide to the preparation of an immunological enhancement medicine. The rhizoma polygonati polysaccharide is obtained by processing raw rhizoma polygonati, extracting and separating; when an extraction method provided by the invention is adopted, the extraction rate of the rhizoma polygonati polysaccharide is high and the content oftotal polysaccharide is high; the proliferation activity of the rhizoma polygonati polysaccharide on normal mouse spleen cells is improved; cyclophosphamide induced spleen and thymus gland index of mice with low immunity also can be improved; the in-vitro proliferation capability of spleen and thymus gland cells under the stimulation of concanavalin A is enhanced; the phagocytic function of macrophage of the mice with the low immunity and the capability of secreting IL-6 and TNF-alpha are enhanced; the rhizoma polygonati polysaccharide has actual application value in the aspect of treatment of diseases including immunodeficiency diseases, tumors and the like.

Methods of treating, preventing and / or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed.

The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

Disclosed is a CpG-N ODN gene sequence with high immunological activity CpG-S ODN and antagonism CpG-N ODN and use in preparing medicament for treating infectious diseases, anaphylactic diseases, immunodeficiency diseases, tumor, SIRS and pyaemia.

Methods are disclosed to identify T lymphocyte genes that are differentially expressed upon exposure to a pathogen (viral or bacterial), immunogen, antigen, or in a sterile inflammatory disease, autoimmune disease, immunodeficiency disease, lymphocytic cancers, or graft versus host rejection. The method involves the preparation of a gene expression profile of a T lymphocyte population exposed to a pathogen or isolated from a subject having one of the aforementioned pathologies and comparing that profile to a profile prepared from quiescent T lymphocytes. The present invention is useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signalling molecules. Related methods for identifying therapeutic or prophylatic immunomodulatory agents are present. Articles of manufacture are disclosed that comprise selected grouping of nucleic acids, affixed to a solid support, that correspond to genes that are differentially expressed in various populations or subpopulations of T lymphocytes at variations stages of T cell differentiation, in quiescent versus activated T lymphocytes or normal versus diseased T lymphocytes.

The invention discloses applications of magnolol, or isomers of magnolol or salts of compounds that are acceptable in pharmaceutical areas to preparation of medicines for treating cachexia and cancers. The cachexia may be caused by selection of the following groups of diseases, states or damage: cancers, immunodeficiency diseases, infectious diseases, autoimmune diseases, metabolic diseases, chronic bowel, liver, kidney, lung and heart diseases, anorexia nervosa, trauma, burning, malabsorption and anemia. In one embodiment, the medicines can be taken by patients that may suffer from cachexia such as cancers. The invention also provides applications of magnolol, or isomers of magnolol or salts of compounds that are acceptable in pharmaceutical areas to preparation of medicines for treating bladder cancers, especially applications to prevention of tumor growth and cancel cell metastasis of bladder cancers and to improvements of animal survival rates.

A method for expressing the thymopeptide alpha 1 by yeast includes such steps as using PCR technique to amplify the whole-length gene of thymopeptide alpha 1, enzyme severing at both ends, and cloning it to yeast while stably expressing it in yeast. The expressed thymopeptide alpha 1 with very high bioactivity can be used to treat tumor, viral and immunodeficiency diseases, and hypothymism, or used as vaccine intensifier.

The invention discloses a Citrin immunodeficiency disease virulence gene SLC25A13 high frequency mutation screening reagent box, and belongs to the biotechnology field. Four kinds of mutations include a I type mutation, a III type mutation, an X type mutation and an XIX type mutation. Sequence of the Citrin immunodeficiency disease virulence gene SLC25A13 high frequency mutation screening primers are displayed as SEQ ID NO.1-8. The Citrin immunodeficiency disease virulence gene SLC25A13 high frequency mutation screening reagent box comprises the primers, dNTPs, deoxyribonucleic acid (DNA) polymerase, DNA polymerase buffer solution and Tas I restriction enzyme components. The reagent box further comprises reagent for extracting genomic DNA from a full blood sample, four kinds of mutation type normality, homozygote and heterozygote comparison DNA, agarose for nucleic acid electrophoresis, DNA Marker and nucleic acid dyestuff. The primers and the reagent box can easily, fast and accurately screen the four high frequency mutations in the SLC25A13.

Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases.

The invention discloses Citrin immunodeficiency disease pathogenic gene SLC25A13 high-frequency I-type mutation screening primers and kit, belongs to the technical field of biology. Four newly designed primers are provided; a multi-PCR system depending on an ordinary rTaq enzyme is built; whether a sample is I mutation positive or negative or heterozygote can be identified through once PCR and analysis of an electrophoretogram; the primers and the kit are accurate, simple, fast and low in cost. By the screening primers and kit disclosed by the invention, DNA sequencing is not needed; the screening primers and kit are simple, fast and low in cost; the detection result is direct and reliable; the detection time and cost are superior to those of an existing method; the screening primers and kit can be finished by simple common equipment and are suitable for medical and test mechanisms of various regions for fast detection and large-scale population screening of the SLC25A13 high-frequency I-type mutation.

The invention discloses a human immunity enhancer for cancer prevention and treatment. The human immunity enhancer comprises components in parts by weight as follows: 111-222 parts of Echinacea phenol, 144-288 parts of astragaloside, 111-177 parts of chrysin, 333-666 parts of coriolus versicolor polysaccharide, 22-33 parts of diindolymethane, 60-111 parts of resveratrol, 80-111 parts of curcumin,111-222 parts of dihydroquercetin, 111-222 parts of tea polyphenols, 2.22-11.1 parts of L-selenomethionine, 80-130 parts of phosphatidylcholine, 90-140 parts of phosphatidylserine, 444-888 parts of methionine and 3000-4000 parts of a lipidosome matrix emulsion. The natural traditional Chinese medicine extracts and multiple active compounds are matched in proportion, a lipidosome matrix convenientto absorb is adopted, the immunity of the human body can be improved, and cancer, AIDS and other immunodeficiency diseases can be resisted effectively.

The invention relates to a polynuclear flavonoid complex or pharmaceutically acceptable salt, hydrate or solvate thereof and a preparation method and use of the complex. The technical scheme of the invention provides a multifunctional polynuclear flavonoid complex and a preparation method thereof. The invention relates to the polynuclear flavonoid complex. The polynuclear flavonoid complex has multiple central ions, is capable of inhibiting the replication of DNA and promoting the apoptosis of tumor cells and can be used for preparing drugs for preventing and treating tumors and immunodeficiency diseases or animal feeds.

A recombinant alpha-thymosingen-interleukin 2 gene composed of humanized alpha-thymosingen and interleukin 2 and its expression and application are disclosed. It has stronger bioactivity, and can be used to prepare the medicines for treating viral infection, tumor and immunodeficiency diseases.

The invention relates to application of atractylodes macrocephalaon polysaccharide in medicaments or healthcare products for improving kuffer cell immune function, belonging to the technical field of traditional Chinese medicine. According to the application, homemade PAM (atractylodes macrocephalaon polysaccharide) is adopted for testing the influences on the mouse Kupffer cell immune function. The PAM in vitro is acted to a normal Kupffer cell so as to evaluate the immune function and the cell damage situation according to the phagocytosis quantity of neutral red A540, the secreting quantity of NO and TNF (tumor necrosis factor)-alpha as well as the LDH (lactate dehydrogenase) leakage quantity; after in-vivo mice are injected with the PAM, the indexes of the Kupffer cell, the activity of intracellular ACP (acid phosphatase) as well as the serum ALT and GST are detected. The result shows that the PAM intensifies the phagocytosis to the neutral red caused by Kupffer cell, improves the ACP activity as well as increases the generation amount of NO and TNF-alpha. The PAM in vitro does not increase parenchymal hepatic cell LDH leakage, and has no influence on the activities of sALT and sGST, so that the PAM can activate the Kupffer cell immune function, improves the organism disease resistance, and has an actual application value at the treatment aspect of diseases of immunodeficiency disease, tumor and the like.

The invention provides a method for preparing antibodies from human peripheral blood memory B lymphocytes. The method has the advantages of being convenient, rapid and low in cost. By means of the method, a large number of the antibodies can be prepared in vitro, and the prepared antibodies are very important in preventing infection and treating immunodeficiency diseases.

This invention relates to a novel peptide inhibitor of a HIV fusion that disrupts the internal trimeric coiled-coil of gp41, to a pharmaceutical composition that comprise this inhibitor, and to methods of treating immunodeficiency disease, especially HIV, that employ such a pharmaceutical composition.

The invention belongs to the technical field of animal model construction, particularly relates to a preparation method and application of a pancreatic cancer animal model based on a gene knockout Syrian hamster, provides an il2rg gene knockout immunodeficiency Syrian hamster, and a pancreatic cancer animal model based on the il2rg gene knockout immunodeficiency Syrian hamster, and further provides a preparation method of the hamster and pancreatic cancer model, and a use of the hamster and pancreatic cancer model as a model mouse for the pathological and physiological research of the human body. The anatomy, physiology and pathology of the hamster are very similar to those of human beings, the clinical symptoms, tumor biology, metabolic disorders, molecular genetic changes and other aspects of the hamster are almost completely the same as those of human diseases, and the pancreatic cancer animal model based on ZZU001 can more comprehensively observe main characteristics of human pancreatic cancer, so that a reliable and economic animal model is provided for the disease progression and clinical intervention research of pancreatic cancer and other immunodeficiency diseases, and thefar-reaching scientific research significance and important popularization prospects are achieved.

The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides.BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and / or treating a cancer, an immunodeficiency disease or an infectious disease.